Nitric Oxide-Mediated S-Nitrosylation of TSC2 Drives mTOR Dysregulation Across Shank3 and Cntnap2 Models of Autism Spectrum Disorder

Why It Matters

The study links nitric‑oxide signaling to mTOR dysregulation, a convergent pathway in autism, opening new therapeutic avenues targeting NO‑TSC2 interactions. It provides a mechanistic bridge between genetic risk (SHANK3, CNTNAP2) and downstream signaling abnormalities.

Key Takeaways

• NO S‑nitrosylates TSC2 at cysteine 203
• Modified TSC2 undergoes ubiquitination, degrading protein
• TSC2 loss hyperactivates mTOR in excitatory, inhibitory neurons
• nNOS inhibitor 7‑NI restores TSC2, normalizes mTOR signaling
• TSC2‑C203S gene therapy rescues ASD behaviors in mice

Pulse Analysis

The discovery of an NO‑driven S‑nitrosylation event on TSC2 reshapes our understanding of autism’s molecular landscape. While genetic studies have highlighted SHANK3 and CNTNAP2 as high‑confidence risk genes, this work demonstrates how a redox‑based modification can converge on the mTOR hub, a pathway already implicated in tuberous sclerosis and other neurodevelopmental disorders. By mapping the SNO‑proteome and pinpointing TSC2 C203 as a critical node, the researchers provide a tangible link between elevated neuronal nitric oxide synthase activity and downstream translational dysregulation.

Therapeutically, the findings are compelling. Inhibiting neuronal NOS with 7‑nitroindazole (7‑NI) halted TSC2 S‑nitrosylation, prevented its proteasomal degradation, and restored normal mTOR signaling in two distinct ASD mouse models. Moreover, delivering a S‑nitrosylation‑resistant TSC2‑C203S construct directly into the prefrontal cortex corrected behavioral deficits, suggesting that precision interventions at the post‑translational level could complement existing strategies such as mTOR inhibitors or synaptic modulators. These preclinical successes underscore the potential of repurposing nNOS inhibitors, already explored in neurovascular contexts, for ASD treatment trials.

From a translational perspective, the parallel observation of reduced TSC2 and heightened mTOR activity in plasma from children with ASD—including those harboring SHANK3 mutations—validates the clinical relevance of the NO‑TSC2‑mTOR axis. This biomarker signature could aid patient stratification, enabling clinicians to identify individuals who may benefit most from NO‑targeted therapies. As the field moves toward mechanism‑based precision medicine, integrating redox biology with established genetic frameworks offers a promising path to address the unmet therapeutic needs of the autism spectrum.